Radiation safety company Mirion (NYSE: MIR) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 24.5% year on year to $277.8 million. Its non-GAAP profit of $0.12 per share was in line with analysts’ consensus estimates.

Is now the time to buy MIR? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Mirion’s third quarter was marked by robust demand across its core nuclear and medical safety markets, resulting in revenue growth that surpassed Wall Street expectations. Orders grew sharply, particularly in the nuclear power segment, with management highlighting “an impressive 105% increase” in nuclear power orders, excluding acquisitions. CEO Thomas D. Logan attributed the performance to strong backlog conversion and large project wins, noting that the company’s expanding backlog is “doing what is expected: converting into accelerated revenue.” The positive reception from investors reflects confidence in Mirion’s ability to capitalize on sector tailwinds and its execution in turning order momentum into top-line results.

Looking forward, Mirion’s updated outlook is anchored by accelerating demand in nuclear power, ongoing backlog conversion, and continued investment in artificial intelligence (AI) and cybersecurity initiatives. Management emphasized that prioritizing AI and cyber investments over near-term margin targets is a deliberate strategy, with Logan stating, “It would be shortsighted on our part to prioritize a near term margin target to the detriment of an opportunity that we believe will drive long term shareholder value.” The company expects annual margin expansion through operating leverage and software initiatives, despite removing its previous near-term margin target due to increased investment needs and evolving industry dynamics.

Key insights from management’s remarks

Management cited nuclear power order growth, expanding backlog, and ongoing AI and cyber investments as the primary drivers of Q3 performance, with margin pressures partially offset by strong execution in the medical segment.

• Nuclear power order surge: Orders in the nuclear power end market more than doubled year over year, driven by increased capital spending on life extensions and upgrades across the U.S. and Europe, as well as a growing installed base.
• Robust backlog conversion: The company’s backlog rose to $1.25 billion, and management expects $735 million to be recognized as revenue between Q4 2026 and 2027, providing high near-term visibility and derisking the full-year outlook.
• AI and cybersecurity investments: Mirion significantly increased spending on AI and cyber initiatives, viewing these as essential for future product development and operational efficiency, even as these investments create short-term margin headwinds.
• Paragon and Certrec integration: The recently acquired Paragon and Certrec businesses contributed to both order and revenue growth, though legacy contracts at Paragon resulted in some margin contraction within the nuclear and safety segment.
• Medical segment recovery: Organic growth returned to all three medical end markets, led by radiotherapy quality assurance (RTQA), with management noting new leadership and product launches that are expected to position the segment for ongoing recovery despite broader sector challenges.

Drivers of future performance

Mirion’s outlook is underpinned by continued strength in nuclear markets, backlog conversion, and the strategic prioritization of AI and cybersecurity investments to support long-term growth.

• Accelerating nuclear project demand: Management expects sustained order momentum from life extensions, power uprates, and digital transformation projects in nuclear power, with a multi-year cycle driven by regulatory changes and capacity upgrades. This is expected to maintain double-digit organic revenue growth in the nuclear and safety segment.
• Margin expansion balanced by investment: While Mirion remains committed to annual margin expansion through operating leverage and procurement initiatives, near-term margins will be tempered by front-loaded AI and cybersecurity spending, especially as these investments are necessary to enhance internal productivity and develop customer-facing solutions.
• Medical segment stabilization: The medical segment’s growth is expected to continue at a moderate pace, supported by new product releases and leadership hires, though management remains cautious given ongoing volatility in healthcare markets and regional differences in recovery rates.

Catalysts in upcoming quarters

In the coming quarters, our analyst team will be watching (1) the pace of backlog conversion into revenue, particularly in nuclear power and large government projects; (2) the impact of continued AI and cybersecurity investments on both product development and operating margins; and (3) evidence of sustained order momentum from U.S. and European nuclear life extension and digital upgrade projects. Execution on medical segment recovery and the integration of recent acquisitions will also be key markers of progress.

Mirion currently trades at $16.70, up from $15.36 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.